CLARET ASSET MANAGEMENT Corp Trims Stake in Johnson & Johnson (NYSE:JNJ)

CLARET ASSET MANAGEMENT Corp lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 75,153 shares of the company’s stock after selling 1,891 shares during the quarter. Johnson & Johnson comprises 2.0% of CLARET ASSET MANAGEMENT Corp’s portfolio, making the stock its 12th largest position. CLARET ASSET MANAGEMENT Corp’s holdings in Johnson & Johnson were worth $9,723,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. CapWealth Advisors LLC boosted its stake in Johnson & Johnson by 23.3% during the 4th quarter. CapWealth Advisors LLC now owns 145,884 shares of the company’s stock valued at $18,826,000 after purchasing an additional 27,578 shares during the period. Segall Bryant & Hamill LLC boosted its stake in Johnson & Johnson by 6.1% during the 4th quarter. Segall Bryant & Hamill LLC now owns 493,479 shares of the company’s stock valued at $63,683,000 after purchasing an additional 28,245 shares during the period. IHT Wealth Management LLC boosted its stake in Johnson & Johnson by 30.9% during the 4th quarter. IHT Wealth Management LLC now owns 24,154 shares of the company’s stock valued at $3,117,000 after purchasing an additional 5,697 shares during the period. CSat Investment Advisory L.P. boosted its stake in Johnson & Johnson by 13.1% during the 4th quarter. CSat Investment Advisory L.P. now owns 933 shares of the company’s stock valued at $120,000 after purchasing an additional 108 shares during the period. Finally, First Wilshire Securities Management Inc. boosted its stake in Johnson & Johnson by 60.8% during the 4th quarter. First Wilshire Securities Management Inc. now owns 2,646 shares of the company’s stock valued at $341,000 after purchasing an additional 1,000 shares during the period. Institutional investors own 72.01% of the company’s stock.

Shares of JNJ stock opened at $131.33 on Friday. The stock has a 50 day moving average of $129.92 and a two-hundred day moving average of $134.97. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 12 month low of $121.00 and a 12 month high of $148.99. The company has a market capitalization of $346.60 billion, a P/E ratio of 16.06, a P/E/G ratio of 2.22 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The company had revenue of $20.56 billion during the quarter, compared to the consensus estimate of $20.39 billion. During the same quarter last year, the company earned $2.10 EPS. The company’s quarterly revenue was down 1.3% on a year-over-year basis. Sell-side analysts predict that Johnson & Johnson will post 8.59 earnings per share for the current fiscal year.

JNJ has been the subject of several recent analyst reports. Credit Suisse Group set a $156.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, August 27th. Bank of America restated a “hold” rating and set a $150.00 target price on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price for the company. in a research note on Thursday, July 18th. Raymond James decreased their target price on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a research note on Wednesday, July 17th. Finally, Goldman Sachs Group set a $169.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, August 27th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $151.00.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Beige Book

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.